HU205083B - Process for producing isoquinoline derivatives and pharmaceutical compositions comprising such compounds - Google Patents

Process for producing isoquinoline derivatives and pharmaceutical compositions comprising such compounds Download PDF

Info

Publication number: HU205083B
Authority: HU; Hungary
Prior art keywords: formula; hydrogen; alkoxy; compounds; treatment
Prior art date: 1988-01-08

Application number

HU8911A

Other languages

English (en)

Hungarian (hu)

Other versions

HUT52061A (en

Inventor

Klaus Hasspacher

Reto Naef

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-01-08

Filing date

1989-01-03

Publication date

1992-03-30

1989-01-03 Application filed by Sandoz Ag filed Critical Sandoz Ag

1990-06-28 Publication of HUT52061A publication Critical patent/HUT52061A/hu

1992-03-30 Publication of HU205083B publication Critical patent/HU205083B/hu

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 76
238000000034 method Methods 0.000 title claims description 41
230000008569 process Effects 0.000 title claims description 10
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 title 1
150000003839 salts Chemical group 0.000 claims abstract description 37
239000001257 hydrogen Substances 0.000 claims abstract description 36
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 36
210000003979 eosinophil Anatomy 0.000 claims abstract description 28
150000002431 hydrogen Chemical group 0.000 claims abstract description 14
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 13
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 13
238000009825 accumulation Methods 0.000 claims abstract description 8
229910052736 halogen Chemical group 0.000 claims abstract description 6
150000002367 halogens Chemical group 0.000 claims abstract description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 6
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract description 5
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims abstract description 5
230000002401 inhibitory effect Effects 0.000 claims abstract description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
230000004913 activation Effects 0.000 claims abstract description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 4
239000002253 acid Substances 0.000 claims description 33
125000003545 alkoxy group Chemical group 0.000 claims description 21
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
125000000217 alkyl group Chemical group 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
239000007858 starting material Substances 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
206010029897 Obsessive thoughts Diseases 0.000 claims description 4
150000002537 isoquinolines Chemical class 0.000 claims description 4
125000006239 protecting group Chemical group 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 3
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
MJAIGHGDMDYBHJ-UHFFFAOYSA-N 1-[3,5-bis(2-methoxyethoxy)phenyl]-6,7-dimethoxy-3-methylisoquinoline Chemical compound COCCOC1=CC(OCCOC)=CC(C=2C3=CC(OC)=C(OC)C=C3C=C(C)N=2)=C1 MJAIGHGDMDYBHJ-UHFFFAOYSA-N 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
206010061218 Inflammation Diseases 0.000 claims 1
230000003182 bronchodilatating effect Effects 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
238000006798 ring closing metathesis reaction Methods 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 51
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
230000002757 inflammatory effect Effects 0.000 abstract description 11
201000010099 disease Diseases 0.000 abstract description 10
229940124630 bronchodilator Drugs 0.000 abstract description 8
239000000168 bronchodilator agent Substances 0.000 abstract description 4
239000003795 chemical substances by application Substances 0.000 abstract description 4
230000000414 obstructive effect Effects 0.000 abstract description 3
238000011321 prophylaxis Methods 0.000 abstract description 3
208000006673 asthma Diseases 0.000 description 24
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
208000000884 Airway Obstruction Diseases 0.000 description 12
230000001154 acute effect Effects 0.000 description 12
206010003645 Atopy Diseases 0.000 description 11
206010020751 Hypersensitivity Diseases 0.000 description 11
208000026935 allergic disease Diseases 0.000 description 11
208000009079 Bronchial Spasm Diseases 0.000 description 10
208000014181 Bronchial disease Diseases 0.000 description 10
206010006482 Bronchospasm Diseases 0.000 description 10
206010014950 Eosinophilia Diseases 0.000 description 10
239000000203 mixture Substances 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
230000001684 chronic effect Effects 0.000 description 8
230000009610 hypersensitivity Effects 0.000 description 8
230000001575 pathological effect Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
206010061876 Obstruction Diseases 0.000 description 7
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
206010006451 bronchitis Diseases 0.000 description 7
230000000694 effects Effects 0.000 description 7
230000002327 eosinophilic effect Effects 0.000 description 7
239000000843 powder Substances 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
208000027771 Obstructive airways disease Diseases 0.000 description 6
230000035508 accumulation Effects 0.000 description 6
-1 hydroxy, methoxy, ethoxy Chemical group 0.000 description 6
208000027866 inflammatory disease Diseases 0.000 description 6
238000002636 symptomatic treatment Methods 0.000 description 6
208000012657 Atopic disease Diseases 0.000 description 5
230000000572 bronchospasmolytic effect Effects 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
206010035653 pneumoconiosis Diseases 0.000 description 5
230000029058 respiratory gaseous exchange Effects 0.000 description 5
210000002345 respiratory system Anatomy 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000003556 assay Methods 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
230000003449 preventive effect Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
238000012360 testing method Methods 0.000 description 4
210000003437 trachea Anatomy 0.000 description 4
102000013585 Bombesin Human genes 0.000 description 3
108010051479 Bombesin Proteins 0.000 description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
206010010741 Conjunctivitis Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
208000037656 Respiratory Sounds Diseases 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
206010047924 Wheezing Diseases 0.000 description 3
230000007815 allergy Effects 0.000 description 3
230000002921 anti-spasmodic effect Effects 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
239000002585 base Substances 0.000 description 3
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
230000000857 drug effect Effects 0.000 description 3
239000000428 dust Substances 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
201000009732 pulmonary eosinophilia Diseases 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000005303 weighing Methods 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
206010003557 Asthma exercise induced Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
241000700198 Cavia Species 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
229920000742 Cotton Polymers 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
208000027004 Eosinophilic disease Diseases 0.000 description 2
208000004657 Exercise-Induced Asthma Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
208000009525 Myocarditis Diseases 0.000 description 2
241000208125 Nicotiana Species 0.000 description 2
235000002637 Nicotiana tabacum Nutrition 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
208000024780 Urticaria Diseases 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
201000009961 allergic asthma Diseases 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
229940124575 antispasmodic agent Drugs 0.000 description 2
201000008937 atopic dermatitis Diseases 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000006356 dehydrogenation reaction Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
201000009580 eosinophilic pneumonia Diseases 0.000 description 2
208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 2
239000012530 fluid Substances 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000011597 hartley guinea pig Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
238000011835 investigation Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
230000007170 pathology Effects 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
WQMSCXCVYMIQHO-UHFFFAOYSA-N 1-(3,5-dimethoxyphenyl)-7-methoxy-3,4-dihydroisoquinolin-6-ol Chemical compound COC1=CC(OC)=CC(C=2C3=CC(OC)=C(O)C=C3CCN=2)=C1 WQMSCXCVYMIQHO-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
208000035872 Allergic myocarditis Diseases 0.000 description 1
208000033116 Asbestos intoxication Diseases 0.000 description 1
201000002909 Aspergillosis Diseases 0.000 description 1
208000036641 Aspergillus infections Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
206010012434 Dermatitis allergic Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000020226 Heiner syndrome Diseases 0.000 description 1
206010062639 Herpes dermatitis Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
208000007924 IgA Deficiency Diseases 0.000 description 1
208000005615 Interstitial Cystitis Diseases 0.000 description 1
208000004852 Lung Injury Diseases 0.000 description 1
206010028594 Myocardial fibrosis Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010035742 Pneumonitis Diseases 0.000 description 1
208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
206010039915 Selective IgA immunodeficiency Diseases 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
206010069363 Traumatic lung injury Diseases 0.000 description 1
206010065258 Tropical eosinophilia Diseases 0.000 description 1
208000012931 Urologic disease Diseases 0.000 description 1
208000035868 Vascular inflammations Diseases 0.000 description 1
238000005273 aeration Methods 0.000 description 1
208000037883 airway inflammation Diseases 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
239000013566 allergen Substances 0.000 description 1
208000028462 aluminosis Diseases 0.000 description 1
208000010123 anthracosis Diseases 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
239000010425 asbestos Substances 0.000 description 1
206010003441 asbestosis Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
229960004484 carbachol Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
108010015046 cell aggregation factors Proteins 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
201000001352 cholecystitis Diseases 0.000 description 1
239000004927 clay Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
ICLWTJIMXVISSR-UHFFFAOYSA-N gallamine Chemical compound CCN(CC)CCOC1=CC=CC(OCCN(CC)CC)=C1OCCN(CC)CC ICLWTJIMXVISSR-UHFFFAOYSA-N 0.000 description 1
229960003054 gallamine Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000035874 hyperreactivity Effects 0.000 description 1
208000013397 idiopathic acute eosinophilic pneumonia Diseases 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
201000007156 immunoglobulin alpha deficiency Diseases 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
201000010659 intrinsic asthma Diseases 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
239000004571 lime Substances 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
231100000516 lung damage Toxicity 0.000 description 1
230000004199 lung function Effects 0.000 description 1
231100000515 lung injury Toxicity 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000000155 melt Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
208000007892 occupational asthma Diseases 0.000 description 1
208000014055 occupational lung disease Diseases 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical class C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
230000007331 pathological accumulation Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000010453 quartz Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000006941 response to substance Effects 0.000 description 1
229910052895 riebeckite Inorganic materials 0.000 description 1
208000029138 selective IgA deficiency disease Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
208000004003 siderosis Diseases 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
125000001424 substituent group Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
208000014001 urinary system disease Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

HU8911A 1988-01-08 1989-01-03 Process for producing isoquinoline derivatives and pharmaceutical compositions comprising such compounds HU205083B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB888800397A GB8800397D0 (en)	1988-01-08	1988-01-08	Improvements in/relating to organic compounds

Publications (2)

Publication Number	Publication Date
HUT52061A HUT52061A (en)	1990-06-28
HU205083B true HU205083B (en)	1992-03-30

Family

ID=10629678

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU8911A HU205083B (en)	1988-01-08	1989-01-03	Process for producing isoquinoline derivatives and pharmaceutical compositions comprising such compounds

Country Status (28)

Country	Link
US (1)	US4980359A (fr)
JP (1)	JPH0649686B2 (fr)
KR (1)	KR0142686B1 (fr)
AT (1)	AT394365B (fr)
AU (1)	AU622429B2 (fr)
BE (1)	BE1002730A3 (fr)
CA (1)	CA1332944C (fr)
CH (1)	CH678727A5 (fr)
DE (1)	DE3900233C2 (fr)
DK (1)	DK5789A (fr)
ES (1)	ES2010071A6 (fr)
FI (1)	FI90865C (fr)
FR (1)	FR2625743B1 (fr)
GB (2)	GB8800397D0 (fr)
GR (1)	GR1002750B (fr)
HU (1)	HU205083B (fr)
IE (1)	IE61914B1 (fr)
IL (1)	IL88899A (fr)
IT (1)	IT1229523B (fr)
LU (1)	LU87423A1 (fr)
MY (1)	MY103963A (fr)
NL (1)	NL8900029A (fr)
NZ (1)	NZ227561A (fr)
PH (1)	PH25640A (fr)
PL (1)	PL156099B1 (fr)
PT (1)	PT89405B (fr)
SE (1)	SE501548C2 (fr)
ZA (1)	ZA89133B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2723674A (en) *	1951-11-28	1955-11-15	Charles E Harris	Telephone cableman's tent
US3007541A (en) *	1959-02-24	1961-11-07	Jr John B Mast	Temporary covering and support structure therefor
GB8807922D0 (en) *	1988-04-05	1988-05-05	Fujisawa Pharmaceutical Co	Isoquinoline compound & process for preparation thereof
US4956371A (en) *	1989-09-19	1990-09-11	Euroceltique, S.A.	Substituted isoquinolines and methods of using same
GB8921304D0 (en) *	1989-09-20	1989-11-08	Wyeth John & Brother Ltd	New method of treatment and heterocyclic compounds used therein
GB9027055D0 (en) *	1990-12-13	1991-02-06	Sandoz Ltd	Organic compounds
KR930703259A (ko) *	1990-12-17	1993-11-29	알베르투스 빌헬무스 요아네스 쩨스트라텐	살균성 이소퀴놀린 유도체
CA2093577C (fr) *	1992-05-07	2006-01-03	Michael Klaus	Retinoides s-heterocyclique alkyl ou alkoxy substitues
US5350423A (en) *	1992-09-23	1994-09-27	Burlington Industries Inc.	Fabric finishing procedure
GB9322828D0 (en) *	1993-11-05	1993-12-22	Sandoz Ltd	Organic compounds
US5683892A (en) *	1994-12-23	1997-11-04	Smithkline Beecham Corporation	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
WO1996021000A2 (fr) *	1994-12-23	1996-07-11	Smithkline Beecham Corporation	Antagonistes de recombinaison de l'il-5 utiles dans le traitement des troubles induits par l'il-5
US7399837B2 (en) *	1995-12-22	2008-07-15	Smithkline Beecham Corporation	Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) *	1994-12-23	1998-07-21	Smithkline Beecham Corporation	Method for treatment and diagnosis of IL-5 mediated disorders
RU2174123C2 (ru) *	1996-10-28	2001-09-27	Новартис Аг	Производные 8-арил-1,7-нафтиридина и фармацевтическая композиция, обладающая противовоспалительной активностью
GB9622386D0 (en) *	1996-10-28	1997-01-08	Sandoz Ltd	Organic compounds
IT1296985B1 (it) *	1997-12-19	1999-08-03	Zambon Spa	Derivati benzazinici inibitori della fosfodiesterasi 4
CA2360386A1 (fr)	1999-01-15	2000-07-20	Beate Gutterer	6-phenylphenanthridines polysubstitues a activite inhibant pde-iv
EP1212089B1 (fr)	1999-08-21	2006-03-22	ALTANA Pharma AG	Combinaison synergetique de roflumilast et salmeterol
RU2213735C2 (ru) *	2001-09-24	2003-10-10	ГУ Институт технической химии Уральского отделения РАН	Способ получения 1-замещенных 3,3-диметил-3,4-дигидроизохинолинов
AR037517A1 (es) *	2001-11-05	2004-11-17	Novartis Ag	Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
MXPA05010373A (es)	2003-04-01	2005-12-05	Applied Research Systems	Inhibidores de fosfodiesterasas en infertilidad.
JP2010526088A (ja) *	2007-04-30	2010-07-29	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	抗ｉｌ−５抗体を投与するための方法
WO2009120927A2 (fr) *	2008-03-28	2009-10-01	Smithkline Beecham Corporation	Procédés de traitement
KR20110071014A (ko)	2008-10-17	2011-06-27	위스콘신 얼럼나이 리서어치 화운데이션	생물학적으로 활성인 알파-베타 펩티드의 제조 방법
CA3064859A1 (fr)	2017-06-06	2018-12-13	Glaxosmithkline Llc	Compositions biopharmaceutiques et procedes pour patients pediatriques

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB645139A (en) *	1946-10-22	1950-10-25	Servita Gyogyszeryar Es Vegyip	Improved process for the production of isoquinoline derivatives
DE1184344B (de) *	1962-06-16	1964-12-31	Orgamol Sa	Verfahren zur Herstellung von Isochinolinderivaten
US3878215A (en) *	1971-12-01	1975-04-15	Sandoz Ag	2-Alkyl-3-substituted-4-aryl isoquinolines
DE2401453A1 (de) *	1973-01-16	1974-07-18	John James Voorhees	Pharmazeutische zusammensetzung zur behandlung von hautproliferationserkrankungen
US4018927A (en) *	1973-12-17	1977-04-19	The Regents Of The University Of Michigan	Treatment of proliferating skin diseases with papaverine alkaloids
DE2503156A1 (de) *	1974-02-05	1975-08-07	Sandoz Ag	Verfahren zur herstellung neuer heterocyclischer verbindungen
DE2811361A1 (de) *	1978-03-16	1979-09-27	Hoechst Ag	Neue isochinolinaldehyde und verfahren zu ihrer herstellung
DE3244594A1 (de) *	1982-12-02	1984-06-07	Hoechst Ag, 6230 Frankfurt	1-phenylisochinolinderivate und verfahren zu ihrer herstellung, diese verbindung enthaltende pharmazeutische praeparate und deren anwendung
PH25651A (en) *	1986-05-21	1991-08-21	Duphar Int Res	New di, tetrahydroisoquinoline derivatives
HU196758B (en) *	1986-05-21	1989-01-30	Gyogyszerkutato Intezet	Process for production of 3-hidroxi-methil-quinolines and medical compositions containing them

1988
- 1988-01-08 GB GB888800397A patent/GB8800397D0/en active Pending
1989
- 1989-01-03 HU HU8911A patent/HU205083B/hu not_active IP Right Cessation
- 1989-01-04 GB GB8900102A patent/GB2213482B/en not_active Expired - Lifetime
- 1989-01-04 IT IT8947504A patent/IT1229523B/it active
- 1989-01-05 CA CA000587599A patent/CA1332944C/fr not_active Expired - Fee Related
- 1989-01-05 DE DE3900233A patent/DE3900233C2/de not_active Expired - Fee Related
- 1989-01-05 SE SE8900039A patent/SE501548C2/sv unknown
- 1989-01-05 ES ES8900053A patent/ES2010071A6/es not_active Expired
- 1989-01-06 MY MYPI89000013A patent/MY103963A/en unknown
- 1989-01-06 DK DK005789A patent/DK5789A/da not_active Application Discontinuation
- 1989-01-06 IE IE3789A patent/IE61914B1/en not_active IP Right Cessation
- 1989-01-06 NL NL8900029A patent/NL8900029A/nl not_active Application Discontinuation
- 1989-01-06 FI FI890072A patent/FI90865C/fi not_active IP Right Cessation
- 1989-01-06 ZA ZA89133A patent/ZA89133B/xx unknown
- 1989-01-06 IL IL8889989A patent/IL88899A/en not_active IP Right Cessation
- 1989-01-06 PT PT89405A patent/PT89405B/pt not_active IP Right Cessation
- 1989-01-06 FR FR898900128A patent/FR2625743B1/fr not_active Expired - Lifetime
- 1989-01-06 LU LU87423A patent/LU87423A1/fr unknown
- 1989-01-06 PL PL1989277092A patent/PL156099B1/pl unknown
- 1989-01-06 AU AU27795/89A patent/AU622429B2/en not_active Ceased
- 1989-01-06 BE BE8900018A patent/BE1002730A3/fr not_active IP Right Cessation
- 1989-01-06 JP JP1001898A patent/JPH0649686B2/ja not_active Expired - Lifetime
- 1989-01-06 NZ NZ227561A patent/NZ227561A/xx unknown
- 1989-01-06 PH PH38011A patent/PH25640A/en unknown
- 1989-01-07 KR KR1019890000151A patent/KR0142686B1/ko not_active Expired - Fee Related
- 1989-01-09 CH CH59/89A patent/CH678727A5/de not_active IP Right Cessation
- 1989-01-09 GR GR890100008A patent/GR1002750B/el unknown
- 1989-01-09 AT AT0003589A patent/AT394365B/de not_active IP Right Cessation
1990
- 1990-04-10 US US07/507,702 patent/US4980359A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL88899A0 (en)	1989-08-15
FI90865B (fi)	1993-12-31
FI890072A0 (fi)	1989-01-06
GB8900102D0 (en)	1989-03-01
IE890037L (en)	1989-07-08
DK5789A (da)	1989-07-09
ATA3589A (de)	1991-09-15
JPH0649686B2 (ja)	1994-06-29
GR890100008A (el)	1994-03-31
IT8947504A0 (it)	1989-01-04
SE8900039L (sv)	1989-07-09
JPH01213267A (ja)	1989-08-28
IT1229523B (it)	1991-09-04
PT89405B (pt)	1993-09-30
SE501548C2 (sv)	1995-03-13
ZA89133B (en)	1990-09-26
FR2625743A1 (fr)	1989-07-13
FI890072A7 (fi)	1989-07-09
FR2625743B1 (fr)	1990-11-09
PH25640A (en)	1991-08-21
PL277092A1 (en)	1989-09-04
DK5789D0 (da)	1989-01-06
FI90865C (fi)	1994-04-11
MY103963A (en)	1993-10-30
NL8900029A (nl)	1989-08-01
DE3900233C2 (de)	2000-04-27
LU87423A1 (fr)	1989-08-30
PL156099B1 (pl)	1992-02-28
KR0142686B1 (ko)	1998-07-15
US4980359A (en)	1990-12-25
AT394365B (de)	1992-03-25
ES2010071A6 (es)	1989-10-16
GB2213482B (en)	1991-09-11
SE8900039D0 (sv)	1989-01-05
CA1332944C (fr)	1994-11-08
GB2213482A (en)	1989-08-16
AU622429B2 (en)	1992-04-09
CH678727A5 (fr)	1991-10-31
DE3900233A1 (de)	1989-07-20
GB8800397D0 (en)	1988-02-10
BE1002730A3 (fr)	1991-05-21
KR890011851A (ko)	1989-08-22
NZ227561A (en)	1991-11-26
AU2779589A (en)	1989-07-20
GR1002750B (el)	1997-08-26
IL88899A (en)	1994-07-31
HUT52061A (en)	1990-06-28
PT89405A (pt)	1990-02-08
IE61914B1 (en)	1994-11-30

Legal Events

Date	Code	Title	Description
1997-11-28	HPC4	Succession in title of patentee	Owner name: NOVARTIS AG, CH
2001-10-29	HMM4	Cancellation of final prot. due to non-payment of fee

Publication	Publication Date	Title
HU205083B (en)	1992-03-30	Process for producing isoquinoline derivatives and pharmaceutical compositions comprising such compounds
AU600021B2 (en)	1990-08-02	Novel xanthine derivatives
HUT61729A (en)	1993-03-01	Process for producing dihydroisoquinoline derivatives and pharmaceutical compositions comprising such compounds
EP0516297B1 (fr)	1996-10-30	Pyridazine diones et leur utilisation dans le traitement des désordres neurologiques
JP3497554B2 (ja)	2004-02-16	新規プリン誘導体及びその薬学的に許容される塩
AU599981B2 (en)	1990-08-02	Novel pharmaceutical compositions comprising and use of cis- 6-(4-acetanilido)-8,9-dimethoxy-2-methyl-1,2,3,4,4a,-10b- hexanhydro-benzo{c}{1,6}naphthyridine
RU2075477C1 (ru)	1997-03-20	1-//2-(динизший алкиламино)алкил/амино/-4-замещенные тиоксантен-9-оны и фармацевтическая композиция, обладающая противоопухолевой активностью
MXPA04005506A (es)	2004-12-10	Composiciones farmaceuticas de adenosina a2a y agonistas del receptor beta-2-adrenergico.
JPH0559087A (ja)	1993-03-09	ウリジン誘導体及びこれを含有する医薬
MXPA04004930A (es)	2005-04-08	Combinacion farmaceutica.
JPH0374386A (ja)	1991-03-28	ピラジン誘導体およびこれを含有する血小板凝集抑制剤または抗炎症剤
PL154160B1 (pl)	1991-07-31	Sposób wytwarzania nowych pochodnych ksantyny